Unknown

Dataset Information

Cost-effectiveness of computed tomography screening for lung cancer in the United States.


ABSTRACT:

Introduction

A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.

Methods

Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.

Results

Annual screening

SUBMITTER: McMahon PM 

PROVIDER: S-EPMC3202298 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature